Coulter Pharmaceutical, Inc. and Cobra Therapeutics Ltd, the gene therapy subsidiary of ML Laboratories, have entered into a collaboration to jointly develop and commercialise Cobra’s platform gene expression technology. The technology, known as Ubiquitous Chromatin Opening Elements (UCOEs), is a new class of gene expression elements which induce efficient productivity from genes introduced into target Read more about Coulter And Cobra Agree Collaboration[…]